A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.

被引：18

作者：

Pauff, James Michael ^{[1
]}

Papadopoulos, Kyriakos P. ^{[2
]}

Janku, Filip ^{[3
]}

Turk, Anita Ahmed ^{[4
]}

Goyal, Lipika ^{[5
]}

Shroff, Rachna T. ^{[6
]}

Shimizu, Toshio ^{[7
]}

Ikeda, Masafumi ^{[8
]}

Azad, Nilofer Saba ^{[9
]}

Cleary, James M. ^{[10
]}

Peters, Mary Linton Bounetheau ^{[11
]}

Borad, Mitesh J. ^{[12
]}

Jaeckle, Kurt A. ^{[13
]}

Kizilbash, Sani Haider ^{[14
]}

Tupper, Rebecca ^{[15
]}

Furin, Carrie E. ^{[16
]}

Hanley, Matthew P. ^{[15
]}

Hill, Elizabeth Goodwin ^{[16
]}

Xu Xiaojian ^{[16
]}

Harding, James J. ^{[17
]}

机构：

[1] Sarah Cannon Res Inst, Franklin, TN USA

[2] South Texas Accelerated Res Therapeut START, San Antonio, TX USA

[3] MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[4] Indiana Univ, Simon Canc Ctr, Dept Med, Hematol Oncol, Indianapolis, IN 46204 USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Univ Arizona, Ctr Canc, Tucson, AZ USA

[7] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[8] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan

[9] Johns Hopkins Sidney Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA

[10] Dana Farber Canc Inst, Boston, MA 02115 USA

[11] Beth Israel Deaconess Med Ctr, Div Med Oncol, Boston, MA 02215 USA

[12] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA

[13] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA

[14] Mayo Clin, Div Med Oncol, Rochester, MN USA

[15] Loxo Oncol Lilly, Stamford, CT USA

[16] Loxo Oncol Lilly, Indianapolis, IN USA

[17] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.TPS350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS350

引用

页数：2